CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Trial of Pembrolizumab and Ramucirumab in Patients With Progressive Transitional Cell Carcinoma After Treatment With an Immune Checkpoint Inhibitor

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04179110
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:47.061130+00:00
Published At: 2022-02-22T00:00:00+00:00
Record Updated At: 2022-02-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Transitional Cell Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-02-22"
protocolSection.identificationModule.nctId: "NCT04179110"
protocolSection.identificationModule.officialTitle: "A Phase II Trial of Pembrolizumab and Ramucirumab in Patients With Progressive Transitional Cell Carcinoma After Treatment With an Immune Checkpoint Inhibitor"
protocolSection.statusModule.overallStatus: "WITHDRAWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.